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time before switching were examined. Descriptive and Chi-
Square statistical analyses were conducted to determine if dif-
ferences existed among the three cohorts. RESULTS: A total of
1242 patients were analyzed: 490 (39.4%) inﬂiximab plus MTX;
607 (48.9%) etanercept plus MTX; and 145 (11.7%) adali-
mumab plus MTX. Over two-thirds of the patients were female
and the mean age was 50.0 years. The Charlson Co-morbidity
Index and disease staging were similar among the three cohorts.
During the 12 months follow-up, 39 patients (7.9%) in the inﬂix-
imab plus MTX cohort switched compared to 72 patients
(11.9%) in the etanercept group and 23 patients (15.9%) in the
adalimumab group. Chi-Square analyses indicated the differ-
ences were statistically signiﬁcant (p < 0.05) as compared to the
inﬂiximab plus MTX cohort. The inﬂiximab group had an
average time of 195.9 days before switching, compared to 183.1
days in the etanercept group, and 165.3 in the adalimumab
group; this was not statistically signiﬁcant. CONCLUSION: The
rate of switching and time before switching are important mea-
sures of the effectiveness of RA treatment in real world practice.
This study found that inﬂiximab plus MTX is associated with a
longer time before switching and a signiﬁcantly lower switching
rate, as compared to the other anti-TNFs. Further studies are
needed to evaluate the impact of switching on clinical and eco-
nomic outcomes.
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OBJECTIVES: To evaluate persistence of anti-TNF treatment
among rheumatoid arthritis (RA) patients utilizing a managed
care database. METHODS: A retrospective study utilizing the
PharMetrics managed care claims database was conducted. The
ﬁrst anti-TNF (inﬂiximab, etanercept, or adalimumab) encounter
(index date) among RA patients between January 1, 2001 and
January 1, 2004 was identiﬁed. Patients were required to have a
minimum of 12-months of continuous plan eligibility prior to
and following their index biologic date. Three mutually exclu-
sive cohorts were developed based on their index biologic; inﬂix-
imab plus methotrexate (MTX); etanercept plus MTX; and
adalimumab plus MTX. Anti-TNF persistence (%) was deﬁned
as the number of days between the ﬁrst biologic prescription and
their last biologic encounter, divided by 365 and multiplied by
100. Both univariate and multivariate analyses were applied to
determine if differences in persistence existed between the three
cohorts. RESULTS: A total of 1242 patients were analyzed con-
sisting of 490 (39.4%) inﬂiximab plus MTX; 607 (48.9%) etan-
ercept plus MTX; and 145 (11.7%) adalimumab plus MTX.
Over two-thirds of the patients were female and the mean age
was 50.0 years. The Charlson Co-morbidity Index and disease
staging were consistent among the three cohorts. The inﬂiximab
plus MTX cohort was more persistent [78.0% than the other 2
cohorts (etanercept plus MTX 73.6% and adalimumab plus
MTX 70.8%)] and was statistically signiﬁcant (p < 0.05). After
adjusting for potential confounding variables (age, gender,
Charlson co-morbidity index and disease severity), inﬂiximab
patients had 5.4% more persistence than etanercept (p < 0.01),
and 7.0% more than the adalimumab group (p < 0.05). Etaner-
cept patients were more persistent than the adalimumab group,
however, the difference was not signiﬁcant (p > 0.05). CON-
CLUSION: These results indicate that patients on inﬂiximab plus
MTX are more persistent with anti-TNF therapy, compared to
other anti-TNFs. Further studies are needed to evaluate the
impact of persistence on clinical outcomes.
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OBJECTIVES: To compare dosing stability and dose changes,
through a retrospective database analysis, for rheumatoid arthri-
tis (RA) patients taking inﬂiximab over ﬁve years. METHODS:
We utilized medical and pharmacy claims data from the Medstat
MarketScan database. The sample consisted of “new starts” for
inﬂiximab users in the commercial and Medicare population: (a)
with a diagnosis of Rheumatoid Arthritis (RA) (ICD-9 714.xx),
(b) who had at least three documented administrations of inﬂix-
imab between 1999 and 2005, (c) who had no prescription
history for any TNF blocker for a 6 month period prior to the
index infusion, and, (d) who were continuously enrolled for a
minimum of 365 days after their index infusion. We examined
the proportion of inﬂiximab users who showed an increase,
decrease, or no change in dose over time in both groups.
RESULTS: Medicare inﬂiximab users (n = 729) were older (mean
age = 73 years) with higher co-morbid scores (mean score = 9.71)
than commercial users (n = 1903, mean age = 50 years, mean
score = 3.83). Following the index infusion, 30.4% of commer-
cial and 17.7% of Medicare users showed no change; 24.6% of
commercial and 43.1% of Medicare users showed a decrease;
and 44.9% of commercial and 39.2% of Medicare members
showed an increase in their dose. For the ﬁve-year period, the
total average dose change between the ﬁrst and last infusion was
24 mg for the Medicare group and 44 mg for the commercial
group. Medicare members also had a lower starting dose than
commercial members (328 mg vs. 366 mg). CONCLUSION:
This study demonstrates that there is dose stability in RA
patients treated with inﬂiximab, as the dose changed on average,
by less than 3% per year over the ﬁve-year period. Further
research is needed to evaluate the impact of dose changes on clin-
ical and economic outcomes.
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OBJECTIVES: Clinicians have long observed a link between
physical pain and a compromised quality of life among the clin-
ical population. However, little is known about the association
between arthritis and the quality of life in the general popula-
tion. This study is designed to identify the impact of arthritis on
the quality of life among adults. METHODS: The Behavioral
Risk Factor Surveillance System (BRFSS) is a state-based,
random-digit-dialed telephone survey of the non-institutional-
ized U.S. population aged 18 years and older. The Ohio BRFSS-
2005 survey, containing 7498 adults was analyzed. As a measure
of Health–Related Quality of Life, the number of “unhealthy
days” during the preceding 30 days was surveyed. All informa-
tion was self-reported. RESULTS: Approximately the same pro-
portion of adults in different age groups experienced at least one
physical unhealthy day in the general adult population (35.6%,
18–44 years old; 37.3%, 45–64 years old; 36.3%, 65 years old
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and older). The impact of arthritis on physical unhealthy days
was stronger among those aged 45–64. (Odds Ratio (OR) = 2.1
for aged 18–44; OR = 3.1 for aged 45–64; OR = 2.1 for aged
65 and older). Unlike a physical unhealthy day, younger people
were more likely to experience a mental unhealthy day in the
general adult population (42.0% for 18–44 years old; 33.4% for
45–64 years old; 17.8% for 65 and older). The impact of arthri-
tis on having mental “unhealthy day” was also stronger among
those aged 45–64 (OR = 1.8 for aged 18–44; OR = 2.3 for aged
45–64; OR = 1.3 for aged 65 and older). CONCLUSION: The
data shows that arthritis has a signiﬁcant impact on the experi-
ence of physical or mental unhealthy days. Although arthritis is
more prevalent among adults aged 65 and older, its impact on
mental “unhealthy days” was stronger among younger adults.
These ﬁndings should be considered in implementing public
health programs.
CANCER—Clinical Outcomes Studies
PCN1
COLONIC STENTING VERSUS SURGERY FOR MALIGNANT
LARGE BOWEL OBSTRUCTION: COMPARATIVE ASSESSMENT
OF OUTCOMES AND COST
Bapat B1, Subramanian S2
1RTI Interntional, Research Triangle Park, NC, USA, 2RTI International,
Waltham, MA, USA
OBJECTIVES: Colorectal cancer is the third most common
malignant neoplasm worldwide and the second leading cause of
cancer deaths in the United States. Advanced colorectal cancer
often presents as large bowel obstruction. With colonic stenting
the creation of a stoma can be avoided and procedural mortal-
ity can be reduced. The objective of this study is to compare the
outcomes and cost of colonic stenting compared to surgery for
large bowel obstruction. METHODS: We used the 2001
Medicare Standard Analytic Files to identify patients who under-
went colon stenting and surgery for large bowel obstruction
caused by colorectal cancer using a combination of procedure
codes and diagnosis codes. For each patient we analyzed the ﬁrst
stenting procedure (index event) we identiﬁed.. We summarized
patients’ demographic characteristics including age, sex and race.
Outcomes and resource utilization measures (inpatient and out-
patient costs, ER visits, in-hospital mortality, and length of stay)
were computed for the index hospitalization and 90-day follow-
up period. RESULTS: We identiﬁed 212 patients with stent
placements and 969 who underwent surgical intervention. The
two groups were similar in demographics and risk factors. In-
hospital mortality was lower for the stent group compared to the
surgery group but this difference was not statistically signiﬁcant
(8.0% versus 11.4%; p = 0.156). Emergency room visits during
the 90 day follow-up period was signiﬁcantly higher for the
surgery group (11.3% versus 17.0%; p = 0.040). Adjusted cost
for the 90-day follow-up period was $6726 (p = 0.000) lower
for the stent group compared to the surgery group. The 90-day
mortality was similar for the two groups CONCLUSION:
Patients who underwent stent placements appear to have fewer
complications during follow-up as they require fewer emergency
room visits. Stent placement appears to be less expensive than
surgery. Additional analysis with larger sample size and longer
follow-up is required to conﬁrm the results from this study.
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OBJECTIVES: Without accurate tumor localization, radiother-
apeutic efﬁcacy is suboptimal and sources of geometric varia-
tions, such as organ motion and patient movement, can result in
irradiation of normal tissues. An evidence-based health technol-
ogy assessment evaluated whether using a real-time 4D electro-
magnetic tumor tracking system, (Calypso® 4D Localization
System with Beacon® Transponders; “Calypso® 4D Localiza-
tion System;” Calypso Medical, Seattle, Washington), improves
the net health outcomes of patients irradiated for clinically local-
ized prostate cancer. METHODS: We addressed the following
questions: 1) Does the Calypso® 4D Localization System accu-
rately localize prostate tumors? 2) Does real-time 4D electro-
magnetic tracking reduce radiation-induced toxicity? 3) How do
the outcomes of real-time 4D electromagnetic tracking compare
to those of alternative technologies? Comparators included 
electronic portal imaging devices, computed tomography, 
ultrasound, and stereoscopic X-ray. We searched electronic 
bibliographic databases and systematically reviewed studies
reporting target shifts between treatment and linear accelerator
isocenters, percentages of shifts exceeding tolerable limits, radi-
ation-induced toxicities, and quality of life measurements.
Unpublished data on the Calypso® 4D Localization System were
also reviewed. RESULTS: Based on 1027 intra-subjects compar-
isons, the Calypso® 4D Localization System was statistically sig-
niﬁcantly (P < 0.0001) concordant with standard radiographic
localization. One prospective multicenter clinical trial showed
that the Calypso® 4D Localization System detected clinically
meaningful misalignments in 1174 of 1524 (77%) treatments for
41 patients positioned by conventional lasers and skin tattoos.
Complications from Beacon® Transponders placement were
comparable to those of transrectal biopsy and prostatic ﬁducial
implantation. Fifteen of 41 (35%) patients experienced minor
acute bladder toxicities; none experienced acute rectal compli-
cations. CONCLUSION: Published evidence suggests that real-
time 4D tracking confers greater accuracy than alternative
methods, but head-to-head clinical trials are lacking and there
are currently no alternative methods for real-time tumor track-
ing. This technology may also reduce overall treatment-related
morbidity; however, we await mature data on late toxicities and
tumor control.
PCN3
CORRELATION BETWEEN TIME TO PROGRESSION AND
OVERALL SURVIVAL IN PATIENTS WITH METASTATIC
BREAST CANCER
Sherrill B1, Hirst C2,Wu Y1,Amonkar MM3, Stein S3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI Health
Solutions, Manchester, UK, 3GlaxoSmithKline, Collegeville, PA, USA
OBJECTIVES: The relationship between disease progression
endpoints and overall survival (OS) has been demonstrated in
colorectal, colon and non-small lung cancers (Johnson et al.
Lancet 2006; Sargent et al. JCO 2005). Patient access to novel
and efﬁcacious therapies for metastatic breast cancer (MBC)
could be expedited if disease progression was documented as a
valid surrogate outcome for OS in pivotal clinical trials. We
assessed the correlation between time to tumor progression
